Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company
Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here.
Prime Medicine Inc. (PRME)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 5,368,526 | $18,628,784 | -2% | 0.12% |
| 2. | Casdin Capital Eli Casdin | 3,167,175 | $10,990,097 | 0.68% | |
| 3. | Balyasny Asset Management Dmitry Balyasny | 3,124,362 | $10,841,536 | +6427% | 0.01% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 3,002,844 | $10,419,869 | +1% | 0.04% |
| 5. | D E Shaw D. E. Shaw | 1,551,369 | $5,383,250 | -30% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.30 | 1,500,000 | $4,950,000.00 | 3,262,440 | 2025-08-01 | Filing | |
| $3.30 | 3,030,300 | $9,999,990.00 | 6,230,300 | 2025-08-01 | Filing | |
| $3.30 | 3,030,300 | $9,999,990.00 | 6,230,300 | 2025-08-01 | Filing | |
| $3.30 | 3,030,300 | $9,999,990.00 | 6,230,300 | 2025-08-01 | Filing | |
| $2.52 | 21,000 | $52,829.70 | 20,240,945 | 2025-06-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.97 | 19,003 | $284,495.81 | 0 | 2023-06-21 | Filing | |
| $15.06 | 37,405 | $563,248.23 | 0 | 2023-06-20 | Filing | |
| $15.02 | 6,532 | $98,109.33 | 0 | 2023-06-16 | Filing | |
| $14.92 | 66,659 | $994,325.64 | 0 | 2023-06-15 | Filing | |
| $14.87 | 28,960 | $430,684.43 | 0 | 2023-06-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,562,498 | $57,471,868 | 2.23% | |
| 2. | 8,268,843 | $28,692,886 | 0% | |
| 3. | 6,467,872 | $22,443,516 | 0% | |
| 4. | 5,095,510 | $17,681,420 | 0% | |
| 5. | 3,245,506 | $11,261,906 | 0.01% |
News See All
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases
Prime Medicine Inc. (NASDAQ:PRME) is one of the best biotech penny stocks to buy according to analysts.
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data
Prime Medicine, Inc.
10 Best Biotech Penny Stocks to Buy According to Analysts
On December 24, Jared Holz of Mizuho joined 'Power Lunch' on CNBC to talk about how to play biotech moving into 2026.
JonesTrading Maintains a Buy on Prime Medicine (PRME)
Prime Medicine Inc. (NASDAQ:PRME) is one of the best biotech penny stocks to buy right now. On July 7, JonesTrading analyst Soumit Roy maintained a Buy rating on Prime Medicine Inc.
14 Best Biotech Penny Stocks to Buy Right Now
He acknowledged that biotech has been a “super tough sector” either way, as there are hundreds of publicly traded stocks that do not add up to anything in aggregate.
10 Hot Penny Stocks to Invest in Now
CNBC reported that consumer prices rose 2.7% year-over-year in June, suggesting that President Trump's tariffs are starting to be felt across the economy.
Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data
Prime Medicine Inc. (NASDAQ:PRME) is one of the best hot stocks to buy according to Wall Street analysts.
11 Best Hot Stocks to Buy According to Wall Street Analysts
On July 1, Ralph Schlosstein, Evercore's chairman emeritus and BlackRock's co-founder, joined 'Closing Bell Overtime' on CNBC to talk about his outlook for markets heading into the second half of the ...
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty
On Tuesday, Citi downgraded Prime Medicine Inc. (NASDAQ:PRME) from a Buy to a Neutral rating while also significantly reducing its price target from $10 to $1.50.
Hedge Fund Resource Center